EyeVision Pharma
- Biotech or pharma, therapeutic R&D
EyeVision Pharma’s (EP) mission is to end the myopia epidemic. EP is seeking investment and partnering opportunities to develop ocular restricted combination therapies to inhibit the axial elongation of the eye, the underlying cause for pathogenesis and progression of myopia. EP has filed multiple patents covering repurposing drug combinations and novel linker library for conjugating drugs into single NCEs for effective delivery and superior clinical outcomes.
Team:
Dr. G. Sridhar Prasad, CEO and Cofounder (https://www.linkedin.com/in/gsprasad/)
Dr. Ranjay Chakraborty, CSO and Cofounder (https://www.linkedin.com/in/ranjay-chakraborty-1439a028/)
Mr. Roger E Bendalac, COO (https://www.linkedin.com/in/rogerebendelac/)
Dr. Allan E. Rubenstein, MD, Chairman, SAB (https://www.linkedin.com/in/allan-rubenstein-5289b211/)
Dr. Krishna Sharma, Advisor, (https://cafnr.missouri.edu/directory/krishna-sharma/)
Dr. Machelle Pardue, Collaborator (https://www.linkedin.com/in/machelle-pardue-26aa4958/)
Address
New YorkNew York
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}